Allarity Therapeutics Inc (ALLR) - News Archive

: This article explores recent important measures undertaken by Allarity Therapeutics, particularly their successful surpassing of Nasdaq s minimum equity requirement and the voluntary withdrawal of Form S-1. This discu...

Allarity Therapeutics, a clinical-stage pharmaceutical company specializing in personalized cancer treatments, has recently announced the early discontinuation of its Phase 2 clinical trial for stenoparib, a novel PARP...

Allarity Therapeutics Achieves Compliance with NASDAQ Minimum Bid Price Requirement, Signalling Positive Growth for Personalized Cancer TreatmentsBoston (April 29, 2024) - Allarity Therapeutics, a leading clinical-stage...

Allarity Therapeutics, a clinical-stage pharmaceutical company focused on developing personalized cancer treatments, has recently received an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5...

Allarity Therapeutics, a clinical-stage pharmaceutical company specializing in the development of personalized oncology therapeutics and companion diagnostics, has announced a significant transition in its leadership. I...